Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 677Heat shock proteins researchUbiquitin and proteasome pathwaysCancer-related Molecular Pathways

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Hsp90 inhibitors as novel cancer chemotherapeutic agents

Neckers, Len·2002·Trends in Molecular Medicine

Abstract

Heat shock protein 90 (Hsp90) is a molecular chaperone whose association is required for the stability and function of multiple mutated, chimeric and over-expressed signaling proteins that promote the growth and/or survival of cancer cells. Hsp90 client proteins include mutated p53, Bcr-Abl, Raf-1, Akt, ErbB2 and hypoxia-inducible factor 1 alpha (HIF-1 alpha). Hsp90 inhibitors, by interacting specifically with a single molecular target, cause the destabilization and eventual degradation of Hsp90 client proteins, and they have shown promising antitumor activity in preclinical model systems. One Hsp90 inhibitor, 17-allylaminogeldanamycin (17AAG), is currently in phase I clinical trial. Because of the chemoprotective activity of several proteins that are Hsp90 clients, the combination of an Hsp90 inhibitor with a standard chemotherapeutic agent could dramatically increase the in vivo efficacy of the therapeutic agent.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1471-4914(02)02316-x

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Research works printed but not linked: 3

  1. Munster, 2001, Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner, Clin. Cancer Res., 7, 2155
  2. Sausville, 2001, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin Cancer Res., 7, 2228
  3. Schulte, 1998, Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin, Cell Stress Chaperones, 3, 100, 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2 · doi:10.1379/1466-1268(1998)003

Cited by

See all 677

Metadata

Authors
Neckers, L.
Affiliations
National Institutes of Health (US)
Corresponding author
Neckers, Len
Venue
Trends in Molecular Medicine
Publisher
Elsevier BV
Published
2002-04
Volume
8
Issue
4
Pages
S55-S61
ISSN
1471-4914 (ISSN-L)
OpenAlex
W2004792969
Cited by
677
References
60
Citations by year
2026: 7 · 2025: 6 · 2024: 12 · 2023: 11 · 2022: 6 · 2021: 5 · 2020: 15 · 2019: 19 · 2018: 11 · 2017: 9 · 2016: 22 · 2015: 20 · 2014: 25 · 2013: 38 · 2012: 25
FWCI
4.70
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Trends in Molecular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
Hsp90 inhibitors, HSP90, molecular chaperones, cancer chemotherapy, client proteins, p53, BCR-ABL, Raf-1, Akt, ERBB2, HIF-1α, combination chemotherapy, protein degradation
MeSH terms
Antibiotics, Antineoplastic, Clinical Trials as Topic, Humans, Neoplasms, Protein-Tyrosine Kinases, Quinones, Transcription Factors, Benzoquinones, HSP90 Heat-Shock Proteins, Lactams, Macrocyclic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hsp90 inhibitors as novel cancer chemotherapeutic agents. https://app.cochat.ai/papers/10.1016/s1471-4914(02)02316-x
The paper
Neckers, L. (2002). Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends in Molecular Medicine. https://doi.org/10.1016/s1471-4914(02)02316-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.